title: Impaired ATP-induced coronary blood flow and diminished aortic NTPDase activity precede lesion formation in apolipoprotein E-deficient mice.
abstract: Intravascular ATP and ADP are important regulators of vascular tone, thrombosis, inflammation, and angiogenesis. This study was undertaken to evaluate the contribution of purinergic signaling to disturbed vasodilation and vascular remodeling during atherosclerosis progression. We used apolipoprotein E-deficient (Apoe(-/-)) mice as an appropriate experimental model for atherosclerosis. Noninvasive transthoracic Doppler echocardiography imaging with adenosine, ATP, and other nucleotides and nonhydrolyzable P2 receptor agonists and antagonists suggests that ATP regulates coronary blood flow in mice through activation of P2Y (most likely, endothelial ATP/UTP-selective P2Y(2)) receptors, rather than via its dephosphorylation to adenosine. Strikingly, compared to age-matched wild-type controls, young (10- to 15-week-old) Apoe(-/-) mice displayed diminished coronary reactivity in response to ATP but not adenosine. The impaired hyperemic response to ATP persisted in older (20- to 30-week-old) Apoe(-/-) mice, which were additionally characterized by mild atherosclerosis (as ascertained by aortic Oil Red O staining) and a systemic increase in plasma ATP and ADP levels. Concurrent thin-layer chromatographic analysis of nucleoside triphosphate diphosphohydrolase (NTPDase) and ecto-5'-nucleotidase/CD73 activities in thoracic aortas, lymph nodes, spleen, and serum revealed that aortic NTPDase was decreased by 40% to 50% in a tissue-specific manner both in young and mature Apoe(-/-) mice. Collectively, disordered purinergic signaling in Apoe(-/-) mice may serve as important prerequisite for impaired blood flow, local accumulation of ATP and ADP at sites of atherogenesis, and eventually, the exacerbation of atherosclerosis.
authors.affiliation: Medicity Research Laboratory and the Department of Medical Microbiology, University of Turku, Turku, Finland.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Mercier
authors.forename: Tuomas O
authors.initials: TO
authors.lastname: Kiviniemi
authors.forename: Antti
authors.initials: A
authors.lastname: Saraste
authors.forename: Mari
authors.initials: M
authors.lastname: Miiluniemi
authors.forename: Johanna
authors.initials: J
authors.lastname: Silvola
authors.forename: Sirpa
authors.initials: S
authors.lastname: Jalkanen
authors.forename: Gennady G
authors.initials: GG
authors.lastname: Yegutkin
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D001013:Aorta, Thoracic / Q000378:metabolism; D001057:Apolipoproteins E / Q000172:deficiency*; D003324:Coronary Artery Disease / Q000503:physiopathology*; D003326:Coronary Circulation / Q000502:physiology*; D005260:Female; D006940:Hyperemia / Q000209:etiology; D008208:Lymphatic System / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D043583:Nucleoside-Triphosphatase / Q000378:metabolism*; D058470:Receptors, Purinergic P2Y / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology; D014664:Vasodilation / Q000502:physiology; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D001057:Apolipoproteins E; D058470:Receptors, Purinergic P2Y; D014665:Vasodilator Agents; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D043583:Nucleoside-Triphosphatase; D000241:Adenosine